Bay City Capital — 2009 Investments

1 investments dated 2009 · listed companies and verified rows first · show all

Vivaldi Biosciencesvivaldibiosciences.comJan 2009

Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.

BiotechHealthtechMedical DevicesFort Collins, US

Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)

Co-investorsNGN Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.